What was filed
Aurobindo Pharma told the exchanges that its wholly owned subsidiary, CuraTeQ Biologics Private Limited, has received approval from ANVISA — Agência Nacional de Vigilância Sanitária, Brazil's National Health Surveillance Agency — for its biosimilars manufacturing facility in Hyderabad. The approval followed a GMP inspection of the facility, which the company said was successfully completed for biological API and sterile products.
Scope of the inspection
Per the filing, the inspection covered four biosimilar products and assessed the mammalian and microbial drug substance manufacturing facility, the prefillable syringe and vial filling facility, packaging and labelling, and QC testing and release laboratories. The company noted that the same drug substance and drug product GMP facility already holds EMA (European Medicines Agency) and WHO certification, with the ANVISA clearance adding a further regulatory endorsement.
Why it matters to a holder
The company framed the approval as strengthening its capability to supply biosimilar products into the Brazilian and broader Latin American markets. For a holder, the filing marks a regulatory milestone that widens the geographies this facility can ship into — a market-access development rather than a disclosed financial outcome. No revenue, order value or supply figures were provided.